, as compared with the 2008 first quarter. The 2% increase, excluding the impact of foreign exchange, was primarily due to higher sales of Wyeth's key pharmaceutical franchises ENBREL
(R) (outside the U.S. and Canada), PREVNAR
(R) and Nutritional products, along with new products TYGACIL
(R), as well as PROTONIX
(R). These increases were partially offset by lower ENBREL
alliance revenue, due primarily to the 2008 first quarter having been positively impacted by Amgen Inc.'s shift to wholesaler distribution, and to a lesser extent, to lower U.S. demand in the 2009 first quarter, as well as by decreased sales of EFFEXOR(R)
(R), due to increased generic competition internationally, and PREMARIN
(R). Excluding the impact of foreign exchange, net revenue for the Pharmaceutical and Animal Health segments increased 2% and 13%, respectively, while the Consumer Healthcare segment decreased 1%.
Gross margin, as a percentage of net revenue, excluding certain significant items, increased 1.8 percentage points to 75.6% for the 2009 first quarter from 73.8% for the 2008 first quarter. The increase was primarily due to the impact of foreign exchange rates and favorable manufacturing variances during the 2009 first quarter.
Selling, general and administrative expenses, excluding certain significant items, decreased 4% for the 2009 first quarter versus the 2008 first quarter and increased 3%, excluding the impact of foreign exchange. This constant dollar increase was primarily due to increased pension expense in the 2009 first quarter, which was partially offset by cost savings related to the Company's productivity initiatives.
Research and development expenses, excluding certain significant items, decreased 6% for the 2009 first quarter versus the 2008 first quarter and decreased 4%, excluding the impact of foPage: 1 2 3 4 5 6 7 8 9 10 11 12 Related medicine news :1
. Wyeth and Nycomed Announce Court Denial of Preliminary Injunction2
. Wyeths Pearl River, N.Y. Facility Celebrates 100 Years of Achievements in Health care3
. Wyeth Announces Election of Bernard Poussot as CEO of Company Effective January 1, 20084
. Wyeth Announces the Election of Robert M. Amen to Its Board of Directors5
. Wyeth Comments on PREVNAR and Trends in Pneumococcal Disease6
. Wyeth to Appeal Nevada Hormone Therapy Trial Verdict7
. Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months8
. Wyeth Consumer Healthcare Initiates Voluntary Recall and Replacement Program for Several Robitussin Products and Childrens Dimetapp Cold & Chest Congestion9
. Wyeth Consumer Healthcare Announces the Availability of Centrum Cardio and New Formula Centrum Products10
. Wyeth to Present at the Credit Suisse First Boston Healthcare Conference11
. Wyeth Receives FDA Approval of Protonix for Delayed-Release Oral Suspension